Promoter SNPs in G1/S checkpoint regulators and their impact on the susceptibility to childhood leukemia

Blood

Volumn 109, Issue 2, 2007, Pages 683-692

  Healy, Jasmine ^a   Bélanger, Hélène ^a   Beaulieu, Patrick ^a   Larivière, Mathieu ^a   Labuda, Damian ^a,b   Sinnett, Daniel ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANADA; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; FAMILY STUDY; FEMALE; FRANCE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; REGULATOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; B CELL LEUKEMIA; COMPARATIVE STUDY; GENETIC PREDISPOSITION; GENETICS; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; FEMALE; G1 PHASE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, PRE-B-CELL; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); S PHASE;

EID: 33846217297     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-02-003236     Document Type: Article

References (68)

1. Stiller CA. Epidemiology and genetics of childhood cancer. Oncogene. 2004;23:6429-6444.
2. Alves S, Amorim A, Ferreira F, Norton L, Prata MJ. The GSTM1 and GSTT1 genetic polymorphisms and susceptibility to acute lymphoblastic leukemia in children from north Portugal. Leukemia. 2002;16:1565-1567.
3. Canalle R, Burim RV, Tone LG, Takahashi CS. Genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia. Environ Mol Mutagen. 2004;43:100-109.
4. Chen CL, Liu Q, Pui CH, et al. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood. 1997;89:1701-1707.
5. Joseph T, Kusumakumary P, Chacko P, Abraham A, Radhakrishna Pillai M. Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children. Pediatr Blood Cancer. 2004;43:560-567.
6. Krajinovic M, Labuda D, Richer C, Karimi S, Sinnett D. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood. 1999;93:1496-1501.
7. Krajinovic M, Labuda D, Sinnett D. Glutathione S-transferase P1 genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukaemia. Pharmacogenetics. 2002;12:655-658.
8. Krajinovic M, Richer C, Sinnett H, Labuda D, Sinnett D. Genetic polymorphisms of N-acetyltransferases 1 and 2 and gene-gene interaction in the susceptibility to childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev. 2000;9:557-562.
9. Krajinovic M, Sinnett H, Richer C, Labuda D, Sinnett D. Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int J Cancer. 2002;97:230-236.
10. Pakakasama S, Mukda E, Sasanakul W, et al. Polymorphisms of drug-metabolizing enzymes and risk of childhood acute lymphoblastic leukemia. Am J Hematol. 2005;79:202-205.
11. Wiemels JL, Smith RN, Taylor GM, Eden OB, Alexander FE, Greaves MF. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci U S A. 2001;98:4004-4009.
12. Smith MT, Wang Y, Skibola CF, et al. Low NAD-(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. Blood. 2002;100:4590-4593.
13. Joseph T, Kusumakumary P, Chacko P, Abraham A, Pillai MR. DNA repair gene XRCC1 polymorphisms in childhood acute lymphoblastic leukemia. Cancer Lett. 2005;217:17-24.
14. Mathonnet G, Krajinovic M, Labuda D, Sinnett D. Role of DNA mismatch repair genetic polymorphisms in the risk of childhood acute lymphoblastic leukaemia. Br J Haematol. 2003;123:45-48.
15. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001;1:222-231.
16. Ivanchuk SM, Rutka JT. The cell cycle: accelerators, brakes, and checkpoints. Neurosurgery. 2004;54:692-699; discussion 699-700.
17. Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 1999;39:295-312.
18. Chang BL, Zheng SL, Isaacs SD, et al. A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Res. 2004;64:1997-1999.
19. Debniak T, Scott RJ, Huzarski T, et al. CDKN2A common variants and their association with melanoma risk: a population-based study. Cancer Res. 2005;65:835-839.
20. Harland M, Taylor CF, Bass S, et al. Intronic sequence variants of the CDKN2A gene in melanoma pedigrees. Genes Chromosomes Cancer. 2005;43:128-136.
21. Kibel AS, Suarez BK, Belani J, et al. CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res. 2003;63:2033-2036.
22. Rodrigues FC, Kawasaki-Oyama RS, Fo JF, et al. Analysis of CDKN1A polymorphisms: markers of cancer susceptibility? Cancer Genet Cytogenet. 2003;142:92-98.
23. Sauroja I, Smeds J, Vlaykova T, et al. Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer. 2000;28:404-414.
24. Lukas J, Groshen S, Saffari B, et al. WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. Am J Pathol. 1997;150:167-175.
25. Banerjee P, Bahlo M, Schwartz JR, et al. SNPs in putative regulatory regions identified by human mouse comparative sequencing and transcription factor binding site data. Mamm Genome. 2002;13:554-557.
26. Pastinen T, Hudson TJ. Cis-acting regulatory variation in the human genome. Science. 2004;306:647-650.
27. Yasuda T, Takeshita H, Nakazato E, et al. The molecular basis for genetic polymorphism of human deoxyribonuclease II (DNase II): a single nucleotide substitution in the promoter region of human DNase II changes the promoter activity. FEBS Lett. 2000;467:231-234.
28. Li LC, Chui RM, Sasaki M, et al. A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res. 2000;60:873-876.
29. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998;3:508-511.
30. Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol. 2000;23:290-296.
31. Pihlajamaki J, Karjalainen L, Karhapaa P, et al. G-250A substitution in promoter of hepatic lipase gene is associated with dyslipidemia and insulin resistance in healthy control subjects and in members of families with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2000;20:1789-1795.
32. Lopez ER, Zwermann O, Segni M, et al. A promoter polmorphism of the CYP27B1 gene is associated with Addison's disease, Hashimoto's thyroiditis, Grave's disease and type 1 diabetes mellitus in Germans. Eur J Endocrinol. 2004;151:193-197.
33. Ho SY, Wang YJ, Chen HL, et al. Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the -308 tumor necrosis factor-alpha promoter gene. Cancer Causes Control. 2004;15:657-663.
34. Baccichet A, Qualman SK, Sinnett D. Allelic loss in childhood acute lymphoblastic leukemia. Leuk Res. 1997;21:817-823.
35. Bourgeois S, Labuda D. Dynamic allele-specific oligonucleotide hybridization on solid support (DASO). Anal Biochem. 2004;324:309-311.
36. Labuda D, Krajinovic M, Richer C, et al. Rapid detection of CYP1A1, CYP2D6, and NAT variants by multiplex polymerase chain reaction and allele-specific oligonucleotide assay. Anal Biochem. 1999;275:84-92.
37. National Center for Biotechnology Information. dbSNP home page. http://www.ncbi.nlm.nih.gov/projects/SNP/. Accessed September 2005.
38. Belanger H, Beaulieu P, Moreau C, Labuda D, Hudson TJ, Sinnett D. Functional promoter SNPs in cell cycle checkpoint genes. Hum Mol Genet. 2005;14:2641-2648.
39. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68:978-989.
40. Excoffier L, Laval G, Schneider S. Arlequin ver. 3.0: an integrated software package for population genetics data analysis. Evol Bioinform Online. 2005;1:47-50.
41. Seltman H, Roeder K, Devlin B. Evolutionary-based association analysis using haplotype data. Genet Epidemiol. 2003;25:48-58.
42. Laird NM, Horvath S, Xu X. Implementing a unified approach to family-based tests of association. Genet Epidemiol. 2000;19:S36-S42.
43. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical approach and powerful approach for multiple testing. J R Stat Soc B. 1995;57:289-300.
44. Sinnett D, Beaulieu P, Belanger H, et al. Detection and characterization of DNA variants in the promoter regions of hundreds of human disease candidate genes. Genomics. 2006;87:704-710.
45. Harland M, Holland EA, Ghiorzo P, et al. Mutation screening of the CDKN2A promoter in melanoma families. Genes Chromosomes Cancer. 2000;28:45-57.
46. Pollock PM, Stark MS, Palmer JM, et al. Mutation analysis of the CDKN2A promoter in Australian melanoma families. Genes Chromosomes Cancer. 2001;32:89-94.
47. International HapMap project. http://www.hapmap.org. Accessed September 2005.
48. Cartharius K, Frech K, Grote K, et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics. 2005;21:2933-2942.
49. Knapp M. A note on power approximations for the transmission/ disequilibrium test. Am J Hum Genet. 1999;64:1177-1185.
50. Tu IP, Balise RR, Whittemore AS. Detection of disease genes by use of family data, II: application to nuclear families. Am J Hum Genet. 2000;66:1341-1350.
51. Horvath S, Wei E, Xu X, Palmer LJ, Baur M. Family-based association test method: age of onset traits and covariates. Genet Epidemiol. 2001;21:S403-S408.
52. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501-1512.
53. Labuda D, Zietkiewicz E, Labuda M. The genetic clock and the age of the founder effect in growing populations: a lesson from French Canadians and Ashkenazim. Am J Hum Genet. 1997;61:768-771.
54. Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol. 1996;16:859-867.
55. Ezoe S, Matsumura I, Satoh Y, Tanaka H, Kanakura Y. Cell cycle regulation in hematopoietic stem/progenitor cells. Cell Cycle. 2004;3:314-318.
56. Golay J, Basilico L, Loffarelli L, Songia S, Broccoli V, Introna M. Regulation of hematopoietic cell proliferation and differentiation by the myb oncogene family of transcription factors. Int J Clin Lab Res. 1996;26:24-32.
57. Furukawa Y, Kikuchi J, Nakamura M, Iwase S, Yamada H, Matsuda M. Lineage-specific regulation of cell cycle control gene expression during haematopoietic cell differentiation. Br J Haematol. 2000;110:663-673.
58. Debniak T, Gorski B, Scott RJ, et al. Germline mutation and large deletion analysis of the CDKN2A and ARF genes in families with multiple melanoma or an aggregation of malignant melanoma and breast cancer. Int J Cancer. 2004;110:558-562.
59. Lamperska K, Karezewska A, Kwiatkowska E, Mackiewicz A. Analysis of mutations in the p16/CDKN2A gene in sporadic and familial melanoma in the Polish population. Acta Biochim Pol. 2002;49:369-376.
60. Mantelli M, Barile M, Ciotti P, et al. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families. Am J Med Genet. 2002;107:214-221.
61. Judson R, Stephens JC. Notes from the SNP vs. haplotype front. Pharmacogenomics. 2001;2:7-10.
62. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia. 1998;12:845-859.
63. Bertin R, Acquaviva C, Mirebeau D, Guidal-Giroux C, Vilmer E, Cave H. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2003;37:44-57.
64. Kiyokawa H, Kineman RD, Manova-Todorova KO, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell. 1996;85:721-732.
65. Nakayama K, Ishida N, Shirane M, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 1996;85:707-720.
66. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haploinsufficient for tumour suppression. Nature. 1998;396:177-180.
67. Shaffer DR, Viale A, Ishiwata R, et al. Evidence for a p27 tumor suppressive function independent of its role regulating cell proliferation in the prostate. Proc Natl Acad Sci U S A. 2005;102:210-215.
68. Labuda D, Krajinovic M, Sabbagh A, Infante-Rivard C, Sinnett D. Parental genotypes in the risk of a complex disease. Am J Hum Genet. 2002;71:193-197.